STOCK TITAN
  1. Home
  2. News
  3. VIRX

Viracta Therapeutics, Inc. - VIRX STOCK NEWS

Welcome to our dedicated page for Viracta Therapeutics news (Ticker: VIRX), a resource for investors and traders seeking the latest updates and insights on Viracta Therapeutics stock.

Viracta Therapeutics, Inc. (symbol: VIRX) is a precision oncology company dedicated to developing innovative therapies targeting virus-associated cancers, particularly those linked to the Epstein-Barr Virus (EBV). The company is pioneering a proprietary viral gene activation therapy aimed at treating serious virus-associated diseases.

Viracta is currently conducting three clinical trials for its combination product candidate, designed as a potential treatment for relapsed/refractory EBV-positive lymphoma. This product candidate integrates nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), with valganciclovir, an FDA-approved antiviral drug used to treat cytomegalovirus (CMV) infections.

The company’s research focuses on advancing its Nana-val (nanatinostat and valganciclovir) therapy through various phases of clinical trials. Recent projects include the Phase 1b/2 study of Nana-val in recurrent/metastatic EBV+ nasopharyngeal carcinoma (NPC) and other EBV+ solid tumors.

Viracta Therapeutics is committed to delivering breakthrough treatments that address the unmet medical needs of patients with virus-associated malignancies. The company continues to establish partnerships and collaborations to enhance its research and development capabilities, ensuring a robust pipeline of innovative therapies.

For the latest updates and further information, please visit www.viracta.com.

News

Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers

Rhea-AI Summary
Viracta Therapeutics plans to highlight new preliminary clinical and preclinical data from studies of its investigational therapy targeting EBV-associated cancers during an R&D Day. The data showed overall response rates of 40% in relapsed/refractory EBV+ peripheral T-cell lymphoma and a sustained overall response rate of 67% in relapsed/refractory EBV+ diffuse large B-cell lymphoma. Positive response and durability data were also observed in recurrent/metastatic EBV+ nasopharyngeal carcinoma. The company is on track to engage with the FDA in 2024 for potential accelerated approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.68%
Tags
conferences
-
News

Viracta Therapeutics to Host R&D Day on October 4, 2023

Rhea-AI Summary
Viracta to host R&D Day on October 4, 2023, to discuss Nana-val therapy for EBV-associated cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
conferences
-
News

Viracta Therapeutics Announces New Employment Inducement Grant

Rhea-AI Summary
Viracta Therapeutics grants Dr. Cohen a non-qualified stock option to purchase 235,000 shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
none
News

Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Viracta Therapeutics achieves efficacy threshold to advance EBV+ peripheral T-cell lymphoma in pivotal NAVAL-1 study. Published Phase 1b/2 clinical trial data shows promising efficacy for Nana-val in relapsed or refractory EBV+ lymphoma. Darrel P. Cohen appointed as Chief Medical Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
earnings
-
News

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

Rhea-AI Summary
Viracta Therapeutics, Inc. (Nasdaq: VIRX) - Phase 1b/2 Trial Data Shows Complete Responses and Ongoing Durable Responses in EBV+ Lymphoma Subtypes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
-
News

Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

Rhea-AI Summary
Viracta Therapeutics, Inc. (VIRX) announced the appointment of Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer (CMO). Dr. Cohen brings over 25 years of clinical research and drug development experience, contributing to successful regulatory submissions of oncology therapies. He will oversee the clinical development and regulatory advancement of Nana-val in EBV-associated malignances, contribute to the strategic expansion of Viracta’s pipeline, and serve on the Executive Leadership Team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
management
News

Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.59%
Tags
none
-
News

Viracta Therapeutics to Present at the Jefferies Healthcare Conference

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.02%
Tags
conferences
-
News

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
conferences
News

Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.22%
Tags
earnings

FAQ

What is the current stock price of Viracta Therapeutics (VIRX)?

The current stock price of Viracta Therapeutics (VIRX) is $0.25 as of December 24, 2024.

What is the market cap of Viracta Therapeutics (VIRX)?

The market cap of Viracta Therapeutics (VIRX) is approximately 9.9M.

What does Viracta Therapeutics, Inc. specialize in?

Viracta Therapeutics specializes in developing therapies targeting virus-associated cancers, particularly those linked to the Epstein-Barr Virus.

What is nanatinostat?

Nanatinostat is a small molecule inhibitor of class I histone deacetylases (HDAC), used in Viracta's combination product candidate for treating EBV-positive cancers.

What is valganciclovir used for?

Valganciclovir is an FDA-approved antiviral drug used to treat and prevent cytomegalovirus (CMV) infections, and it's part of Viracta's combination product candidate.

What are the current projects of Viracta Therapeutics?

Viracta is conducting three clinical trials for its combination product candidate, focusing on the treatment of relapsed/refractory EBV-positive lymphoma.

What is the Nana-val therapy?

Nana-val is a combination of nanatinostat and valganciclovir, currently under investigation as a treatment for EBV-associated cancers.

Where can I find more information about Viracta Therapeutics?

You can visit their website at www.viracta.com for more information and the latest updates.

Who is the contact person for investor relations at Viracta?

Ashleigh Barreto is the Head of Investor Relations & Corporate Communications at Viracta Therapeutics.

What types of cancers is Viracta targeting?

Viracta is primarily targeting cancers associated with the Epstein-Barr Virus, including EBV-positive lymphoma and other EBV+ solid tumors.

How does Viracta's viral gene activation therapy work?

Viracta's therapy aims to activate viral genes to trigger a therapeutic response against virus-associated malignancies.

What is the significance of the Phase 1b/2 study of Nana-val?

This study investigates the efficacy of Nana-val in treating recurrent/metastatic EBV+ nasopharyngeal carcinoma (NPC) and other EBV+ solid tumors.

Stock VIRX logo
Viracta Therapeutics, Inc.

Nasdaq:VIRX

VIRX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends
#24 Top Loser

VIRX Stock Data

9.94M
38.65M
2.84%
50.06%
6.83%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CARDIFF